The short answer: what makes someone a strong candidate

For anyone who has imaging-confirmed cartilage wear and is weighing up whether an injectable treatment could apply to them, the answer with ChondroFiller™ is broader than most patients expect.

ChondroFiller™ is an injectable collagen scaffold placed under ultrasound guidance as an outpatient procedure — not a surgical intervention. The collagen solution is delivered directly into the joint, where it gels in situ and provides a structural matrix into which the body's own cells can migrate and begin rebuilding cartilage tissue.

Two features set the injection pathway apart from every conventional surgical cartilage repair option. First, there is no upper age limit — patients in their 60s, 70s, and beyond are routinely considered, and a finding of advanced wear or 'bone on bone' on imaging does not automatically exclude someone. Second, there is no defect-size ceiling: because the injectable scaffold can coat the entire articular surface in a single delivery, it is relevant for diffuse joint-wide wear as well as isolated focal lesions — a scope no size-restricted surgical technique can match.

The treatment is indicated for adults with cartilage wear confirmed on imaging across virtually any synovial joint: knee, hip, ankle, shoulder, elbow, wrist, foot, and hand. Both the breadth of eligible joints and the absence of the size and age thresholds that constrain surgical alternatives mean the eligible population is considerably wider than many patients have been led to believe.

Four patient groups that tend to benefit most

Adults who have been told their options are 'wait and see' or joint replacement often find they fit the first group: those with imaging-confirmed cartilage wear who want a non-surgical, joint-preservation-first pathway. Published clinical series indicate that an injectable collagen scaffold can be placed under ultrasound guidance across virtually any affected synovial joint without theatre admission, making this a realistic first active step rather than a holding position.

The second group — active patients in their 60s, 70s, and beyond who have received a recommendation for joint replacement — is where the absence of an age ceiling becomes clinically meaningful. Advanced radiological grading, including Kellgren-Lawrence Grade IV, does not automatically disqualify someone from the injection pathway. Evidence suggests that functional improvement, measured by validated scoring tools in published post-market follow-up studies, can be meaningful and sustained even in joints showing significant structural change.

The third group covers post-traumatic and structural presentations: chondral lesions, osteochondritis dissecans (OCD), and cartilage damage that developed secondary to meniscal injury or following ligament reconstruction. Where the broader joint mechanics are otherwise sound — no active instability, no significant malalignment — clinical selection criteria support the injectable scaffold as a relevant option. The distinction matters because these patients are often younger and not yet candidates for replacement, yet have cartilage loss that is progressive without intervention.

A fourth presentation arises when cartilage loss coexists with active synovitis — a joint that is both worn and inflamed, with recurring swelling or flares alongside structural damage. In this scenario, a combination approach may be considered: the injectable collagen scaffold addresses the cartilage surface, while a separate hydrogel agent targets concurrent inflammation within the joint space. These are distinct mechanisms with distinct roles, and the two are not interchangeable.

What type and grade of cartilage damage qualifies

The question most patients ask at this stage is whether their scan findings are 'bad enough' or 'not bad enough' — and with conventional cartilage surgery, that question genuinely matters. Microfracture is typically only performed for defects smaller than 2–4 cm²; cell-based surgical repair options such as MACI are generally reserved for isolated focal defects larger than that threshold. Between and around those brackets sits a cohort of patients whose damage does not meet either criterion — too diffuse for a focal repair, or too advanced and widespread for a size-limited technique — who are often told no surgical option applies.

The injectable collagen scaffold pathway does not carry a comparable grade filter. Published clinical evaluation data confirm its use across any degree of cartilage wear, from early-stage thinning through to Kellgren-Lawrence Grade IV changes where subchondral bone is exposed on imaging. MRI is the standard confirmatory step — it establishes the distribution, depth, and extent of cartilage involvement and informs which delivery approach is appropriate — but the findings themselves do not set an eligibility ceiling in the way they do for surgical routes.

In practical terms this means the injection pathway may be relevant at both ends of the spectrum. Patients with relatively limited wear that has not yet reached surgical size thresholds have a documented in-scope presentation. So do patients whose joint shows advanced, diffuse involvement across multiple compartments — a pattern that typically falls outside any surgical size criteria altogether. Post-market structural data measured by MRI MOCART scoring, which reached 81.6–84.3 at one year in published European series, indicate meaningful scaffold integration and defect filling even in joints with substantial baseline damage.

A clinical imaging review remains the necessary first step: self-assessment of cartilage grade is not a reliable guide to suitability, and specialist evaluation of the scan is what determines which pathway fits.

Joint mechanics: what needs to be stable before treatment

Addressing the cartilage surface and addressing the forces acting on it are different problems. ChondroFiller™ as an injectable collagen scaffold restores the structural layer of damaged cartilage; it cannot correct the mechanical environment in which that cartilage sits. A clinical assessment will typically consider whether the joint's load-bearing mechanics are stable enough for the scaffold to integrate appropriately once placed.

Three factors commonly reviewed are ligament integrity, joint alignment, and meniscal status. Significant ligament instability — where abnormal joint movement is driving repetitive surface damage — needs to be identified and managed, either before or alongside treatment. Marked malalignment, such as pronounced varus or valgus deformity, concentrates load on a single compartment in a way that may need to be addressed as part of the wider plan. Where a meniscal deficit is actively accelerating cartilage loss, that issue sits upstream of any surface-level repair.

On mechanical load more broadly: no published BMI threshold appears in the available clinical data for this treatment. In practice, clinicians consider significant excess weight as one factor where it plausibly concentrates force on an already-compromised compartment — it is weighed alongside the full clinical picture rather than applied as a fixed exclusion criterion.

Identifying these variables early is not primarily a process of elimination. Most patients with structural factors are not automatically excluded — they may need those issues managed as part of a staged or combined plan. What the mechanics assessment does is determine the most appropriate pathway: the injectable scaffold used alone, alongside structural treatment, or in a phased sequence.

Injection pathway vs surgical cartilage repair: how the routes differ

The injectable scaffold and surgical cartilage repair are separate clinical decisions, not points on the same continuum. Treating one as a stepping stone to the other misrepresents how each route is positioned.

The injection pathway — placed under ultrasound guidance at an outpatient appointment, without theatre admission, incisions, or general anaesthesia — is the described treatment pathway here. It suits joints where wear is diffuse, advanced, or spread across multiple compartments: precisely the pattern that places a joint outside eligibility for most conventional surgical repair techniques.

A separate surgical collagen scaffold pathway exists for a distinct patient profile: isolated, focal Grade III or IV cartilage lesions with intact surrounding borders in an otherwise healthy joint, and sufficient biological capacity to support tissue regeneration. That profile is narrower. The surgical route involves dedicated clinical screening, an operating theatre setting, and a different post-procedure course. It is not a more intensive version of the injection, nor a natural escalation — it is a different route suited to a different presentation.

From a clinical standpoint, the two serve overlapping but non-identical populations. The injection pathway is appropriate for diffuse or advanced wear, including Kellgren-Lawrence Grade IV changes — a range that falls outside conventional surgical repair criteria altogether. Where the surgical criteria are not met, or where a patient prefers to remain outside a surgical pathway, the injectable scaffold is assessed on its own clinical merits.

A specialist imaging review is what determines which route is appropriate. The two pathways are not interchangeable, and neither is a prerequisite for the other.

What the published evidence shows — and where uncertainty remains

Published series report a mean improvement in IKDC functional scores of approximately 32 points at 12 months, sustained and marginally increased at three-year follow-up in the Jerosch et al. prospective study, with patients reaching an average functional score of 80. This consistently exceeds the accepted minimal clinically important difference of 16.7 points — the threshold at which functional gain is considered clinically meaningful rather than incidental. Structural repair data, expressed through MOCART scoring, indicate over 80% defect filling and good integration with surrounding native cartilage at 12 months, with progressive maturation of the repair tissue observed between early and later imaging timepoints.

On safety, published complication rates are low; reoperation rates in the available data compare favourably with those reported for microfracture (up to 41%) and cell-based surgical repair such as MACI (up to 37%).

No randomised controlled trial directly comparing the injection against a no-treatment control has been published at this time. The primary clinical evaluation data are manufacturer-supported — a relevant context — though independent European clinical studies report consistent findings across functional and structural outcome measures. Long-term follow-up data beyond three years for the injection-specific delivery form also remain limited.

Taken together, the evidence base is strongest for patients with focal, imaging-confirmed cartilage defects in a mechanically stable joint — the profile described in the first and third groups earlier in this article. Active older patients pursuing joint preservation, and those with concurrent joint inflammation, are supported by the absence of age or defect-size exclusions and by sound biological rationale, but have less direct outcome data behind them as distinct sub-groups within the current literature.

Determining where an individual sits within this evidence picture requires imaging review and clinical assessment. A structured consultation — not published criteria alone — is what identifies the appropriate pathway.